ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Sanofi Signs Two Bulk Drug Agreements

by Michael McCoy
July 12, 2010 | APPEARED IN VOLUME 88, ISSUE 28

The French drug giant Sanofi-Aventis will carry out contract manufacturing for two biotech firms. Its Sanofi Chimie arm has signed a toll manufacturing agreement under which it will supply the Dutch company Pharming with the active ingredient in Ruconest, a protein treatment for angio­edema that is soon to be launched in several European markets. Pharming says Sanofi will eventually replace Merck & Co., which now supplies Pharming with the bulk drug on a smaller scale. Separately, Sanofi will supply bulk human insulin for an oral form of insulin being developed by Israel’s Oramed Pharmaceuticals.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment